The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Trovan     7-[(1S,5R)-6-amino-3- azabicyclo[3.1.0]hex...

Synonyms: TVFX, Trovafloxacin, CHEMBL428, SureCN34465, SureCN34466, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Fluorinated quinolone


Psychiatry related information on Fluorinated quinolone

  • Using a device developed at our institute for the simultaneous registration of the activity of rats housed in single cages, we have investigated the effects of trovafloxacin, fleroxacin or ofloxacin on the locomotor activity of juvenile and adult rats (11 per group) after oral administration of 600 mg/kg for 5 consecutive days [4].

High impact information on Fluorinated quinolone


Chemical compound and disease context of Fluorinated quinolone


Biological context of Fluorinated quinolone


Anatomical context of Fluorinated quinolone


Associations of Fluorinated quinolone with other chemical compounds


Gene context of Fluorinated quinolone

  • Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin [26].
  • The relevance of this in vitro observation was explored by examining TNF-alpha and IL-6 responses in trovafloxacin-treated mice [27].
  • Twelve hours after initiation of therapy, however, TNF and IL-1beta were higher in trovafloxacin-treated animals (TNF, 61 U/mL versus 7 U/mL; P = 0.001; IL-1beta, 4320 pg/mL versus 427 pg/mL; P = 0.006) [28].
  • In comparison with ceftriaxone, trovafloxacin resulted in lower tumour necrosis factor (TNF) and interleukin 1beta (IL-1beta) CSF levels 2 h after the initiation of treatment (TNF levels, median 26 U/mL versus 141 U/mL; P = 0.02; IL-1beta levels 455 pg/mL versus 1399 pg/mL; P = 0.02) [28].
  • Whether the greater intrinsic activity of trovafloxacin might allow its use in treating MRSA and enterococcal infections remains to be seen [29].

Analytical, diagnostic and therapeutic context of Fluorinated quinolone


  1. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Liguori, M.J., Anderson, M.G., Bukofzer, S., McKim, J., Pregenzer, J.F., Retief, J., Spear, B.B., Waring, J.F. Hepatology (2005) [Pubmed]
  2. Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group. Jones, R.B., Schwebke, J., Thorpe, E.M., Dalu, Z.A., Leone, P., Johnson, R.B. Am. J. Med. (1998) [Pubmed]
  3. Fulminant toxic epidermal necrolysis induced by trovafloxacin. Matthews, M.R., Caruso, D.M., Phillips, B.J., Csontos, L.G. Arch. Intern. Med. (1999) [Pubmed]
  4. Effects of fluoroquinolones on the locomotor activity in rats. Thiel, R., Metzner, S., Gericke, C., Rahm, U., Stahlmann, R. Arch. Toxicol. (2001) [Pubmed]
  5. Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. Olsen, K.M., Gentry-Nielsen, M., Yue, M., Snitily, M.U., Preheim, L.C. Antimicrob. Agents Chemother. (2006) [Pubmed]
  6. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Firsov, A.A., Lubenko, I.Y., Vostrov, S.N., Portnoy, Y.A., Zinner, S.H. Antimicrob. Agents Chemother. (2005) [Pubmed]
  7. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Join-Lambert, O.F., Michéa-Hamzehpour, M., Köhler, T., Chau, F., Faurisson, F., Dautrey, S., Vissuzaine, C., Carbon, C., Pechère, J. Antimicrob. Agents Chemother. (2001) [Pubmed]
  8. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Betriu, C., Gómez, M., Palau, M.L., Sánchez, A., Picazo, J.J. Antimicrob. Agents Chemother. (1999) [Pubmed]
  9. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Ruiz-Serrano, M.J., Alcalá, L., Martínez, L., Díaz, M., Marín, M., González-Abad, M.J., Bouza, E. Antimicrob. Agents Chemother. (2000) [Pubmed]
  10. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Kenny, G.E., Cartwright, F.D. Antimicrob. Agents Chemother. (1996) [Pubmed]
  11. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Cutler, N.R., Vincent, J., Jhee, S.S., Teng, R., Wardle, T., Lucas, G., Dogolo, L.C., Sramek, J.J. Antimicrob. Agents Chemother. (1997) [Pubmed]
  12. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice. Thadepalli, H., Chuah, S.K., Reddy, U., Hanna, N., Clark, R., Polzer, R.J., Gollapudi, S. Antimicrob. Agents Chemother. (1997) [Pubmed]
  13. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Lister, P.D., Sanders, C.C. Antimicrob. Agents Chemother. (1999) [Pubmed]
  14. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Teng, R., Girard, D., Gootz, T.D., Foulds, G., Liston, T.E. Antimicrob. Agents Chemother. (1996) [Pubmed]
  15. Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin. Khan, A.A., Araujo, F.G., Brighty, K.E., Gootz, T.D., Remington, J.S. Antimicrob. Agents Chemother. (1999) [Pubmed]
  16. Effect of trovafloxacin on production of cytokines by human monocytes. Khan, A.A., Slifer, T.R., Remington, J.S. Antimicrob. Agents Chemother. (1998) [Pubmed]
  17. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. París, M.M., Hickey, S.M., Trujillo, M., Shelton, S., McCracken, G.H. Antimicrob. Agents Chemother. (1995) [Pubmed]
  18. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. Stearne, L.E., Vonk, A.G., Kullberg, B.J., Gyssens, I.C. Antimicrob. Agents Chemother. (2005) [Pubmed]
  19. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Edelstein, P.H., Edelstein, M.A., Ren, J., Polzer, R., Gladue, R.P. Antimicrob. Agents Chemother. (1996) [Pubmed]
  20. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Pascual, A., García, I., Ballesta, S., Perea, E.J. Antimicrob. Agents Chemother. (1997) [Pubmed]
  21. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. Bataille, L., Rahier, J., Geubel, A. J. Hepatol. (2002) [Pubmed]
  22. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Wright, D.H., Gunderson, B.W., Hovde, L.B., Ross, G.H., Ibrahim, K.H., Rotschafer, J.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  23. Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS. Lacy, M.K., Nicolau, D.P., Nightingale, C.H., Geffken, A., Teng, R., Vincent, J., Quintiliani, R. Antimicrob. Agents Chemother. (1999) [Pubmed]
  24. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Entenza, J.M., Vouillamoz, J., Glauser, M.P., Moreillon, P. Antimicrob. Agents Chemother. (1999) [Pubmed]
  25. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Lubasch, A., Keller, I., Borner, K., Koeppe, P., Lode, H. Antimicrob. Agents Chemother. (2000) [Pubmed]
  26. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. Bébéar, C.M., Grau, O., Charron, A., Renaudin, H., Gruson, D., Bébéar, C. Antimicrob. Agents Chemother. (2000) [Pubmed]
  27. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin. Purswani, M., Eckert, S., Arora, H., Johann-Liang, R., Noel, G.J. J. Antimicrob. Chemother. (2000) [Pubmed]
  28. Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis. Nau, R., Zysk, G., Schmidt, H., Fischer, F.R., Stringaris, A.K., Stuertz, K., Brück, W. J. Antimicrob. Chemother. (1997) [Pubmed]
  29. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Bonilla, H.F., Zarins, L.T., Bradley, S.F., Kauffman, C.A. Diagn. Microbiol. Infect. Dis. (1996) [Pubmed]
  30. Elevated international normalized ratio associated with trovafloxacin. Goel, K., Menzies, D., Cunha, B.A. Ann. Intern. Med. (1999) [Pubmed]
  31. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Christensson, B.A., Nilsson-Ehle, I., Ljungberg, B., Lindblad, A., Malmborg, A.S., Hjelte, L., Strandvik, B. Antimicrob. Agents Chemother. (1992) [Pubmed]
  32. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Girard, A.E., Girard, D., Gootz, T.D., Faiella, J.A., Cimochowski, C.R. Antimicrob. Agents Chemother. (1995) [Pubmed]
  33. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Wexler, H.M., Molitoris, E., Molitoris, D., Finegold, S.M. Antimicrob. Agents Chemother. (1996) [Pubmed]
WikiGenes - Universities